Protocol Ledger

NCT06418711 · Phase III · TERMINATED

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

Interventional Phase III clinical trial protocol NCT06418711 sponsored by Mannkind in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-11 Enrollment: 132 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06418711
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)132 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06418711
Protocol FieldVerified Registry Value
NCT IdentifierNCT06418711
Consolidated Lead SponsorMannkind
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment132 participants (ACTUAL)
Registered Start Date2024-09-11
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI